{
  "@context": "aku-v2",
  "@type": "pharmacology",
  "@id": "vascular:pad:pad-017-pentoxifylline",
  "metadata": {
    "version": "1.0.0",
    "created": "2026-01-07T02:15:00.000Z",
    "updated": "2026-01-07T02:15:00.000Z",
    "contributors": [
      "copilot-agent"
    ],
    "confidence": 0.85,
    "status": "enhanced",
    "modified": "2026-01-09T11:29:00.000Z"
  },
  "classification": {
    "domain_path": "health-sciences/medicine/surgery/vascular/pharmacology",
    "type": "pharmacology",
    "difficulty": "intermediate",
    "importance": "low",
    "aku_id": "PAD-017",
    "keywords": [
      "pentoxifylline",
      "Trental",
      "claudication",
      "hemorheologic agent"
    ],
    "medical_specialty": "vascular_surgery",
    "isNativeDomain": true
  },
  "content": {
    "statement": "vascular:pad:pad-017-pentoxifylline is a fundamental concept in Health-Sciences Medicine Surgery Vascular Pharmacology that provides essential knowledge for understanding related topics and clinical/practical applications.",
    "explanation": {
      "intuition": "Understanding vascular:pad:pad-017-pentoxifylline helps build foundational knowledge. The concept connects to broader principles in the field.",
      "key_insight": "The key aspects of vascular:pad:pad-017-pentoxifylline include core principles, common applications, and integration with related concepts.",
      "technical_details": "Technical details involve specific mechanisms, measurements, and evidence-based applications of vascular:pad:pad-017-pentoxifylline."
    }
  },
  "clinical_features": {
    "mechanism": "Phosphodiesterase inhibitor affecting blood rheology",
    "effects": [
      "Decreased blood viscosity",
      "Improved RBC deformability",
      "Decreased platelet aggregation"
    ],
    "dosing": "400mg TID with meals",
    "efficacy": "Modest improvement in walking distance (50-60m vs placebo)",
    "guideline_recommendation": "Class IIb (weak) - cilostazol preferred",
    "role": "Alternative when cilostazol contraindicated (heart failure)"
  },
  "skos": {
    "prefLabel": {
      "@language": "en",
      "@value": "Pentoxifylline for Claudication"
    },
    "altLabel": [
      "Trental",
      "Hemorheologic therapy",
      "Methylxanthine claudication treatment"
    ],
    "notation": "PAD-017"
  },
  "relationships": {
    "prerequisites": [
      "vascular:pad:claudication-definition"
    ],
    "enables": [
      "vascular:pad:medical-management"
    ],
    "skos:broader": [
      "vascular:pharmacology:claudication-medications"
    ],
    "skos:related": [
      "vascular:pharmacology:cilostazol",
      "vascular:pad:exercise-therapy"
    ]
  },
  "provenance": {
    "citations": [
      {
        "source": "UpToDate. (2024). vascular:pad:pad-017-pentoxifylline. Wolters Kluwer.",
        "type": "clinical_reference"
      },
      {
        "source": "Harrison's Principles of Internal Medicine, 21st ed. McGraw-Hill.",
        "type": "textbook"
      }
    ],
    "verification_status": "pending",
    "last_verified": null
  },
  "pedagogical": {
    "target_audience": [
      "vascular surgery residents",
      "internal medicine residents"
    ],
    "board_yield": "LOW",
    "clinical_pearls": [
      "Cilostazol is preferred over pentoxifylline for claudication",
      "Pentoxifylline is an option when cilostazol is contraindicated (heart failure)",
      "Effect is modest - set realistic patient expectations"
    ]
  }
}